Pharma Mar, S.A. (LON:0RC6)

Market Cap	1.23B
Revenue (ttm)	147.02M
Net Income (ttm)	16.63M
Shares Out	n/a
EPS (ttm)	n/a
PE Ratio	73.72
Forward PE	23.61
Dividend	0.68 (0.84%)
Ex-Dividend Date	Jun 25, 2025

Volume	1,073
Average Volume	1,551
Open	81.38
Previous Close	80.15
Day's Range	80.05 - 80.85
52-Week Range	35.10 - 105.60
Beta	-0.11
RSI	46.97
Earnings Date	Jul 25, 2025

About Pharma Mar

Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata for the treatment of soft tissue sarcoma and recurrent ovarian cancer; Aplidin i...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1986
• Employees: 500
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RC6

Financial Performance

In 2024, Pharma Mar's revenue was 174.86 million, an increase of 10.56% compared to the previous year's 158.15 million. Earnings were 26.13 million, an increase of 2197.71%.

Financial numbers in EUR